Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China.
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, P.R. China.
Clin Cancer Res. 2019 Mar 15;25(6):1867-1879. doi: 10.1158/1078-0432.CCR-18-1226. Epub 2018 Nov 16.
More than 30% of patients with diffuse large B-cell lymphoma (DLBCL) experience treatment failure after first-line therapy. Neutrophil extracellular traps (NETs), a pathogen-trapping structure in tumor microenvironment, can promote the transition of autoimmunity to lymphomagenesis. Here, we investigate whether NETs play a novel role in DLBCL progression and its underlying mechanism. NETs in DLBCL tumor samples and plasma were detected by immunofluorescence and ELISA, respectively. The correlation between NETs and clinical features were analyzed. The effects of NETs on cellular proliferation and migration and mechanisms were explored, and the mechanism of NET formation was also studied by a series of and assays.
Higher levels of NETs in plasma and tumor tissues were associated with dismal outcome in patients with DLBCL. Furthermore, we identified NETs increased cell proliferation and migration and tumor growth and lymph node dissemination . Mechanistically, DLBCL-derived IL8 interacted with its receptor (CXCR2) on neutrophils, resulting in the formation of NETs via Src, p38, and ERK signaling. Newly formed NETs directly upregulated the Toll-like receptor 9 (TLR9) pathways in DLBCL and subsequently activated NFκB, STAT3, and p38 pathways to promote tumor progression. More importantly, disruption of NETs, blocking IL8-CXCR2 axis or inhibiting TLR9 could retard tumor progression in preclinical models.
Our data reveal a tumor-NETs aggressive interaction in DLBCL and indicate that NETs is a useful prognostic biomarker and targeting this novel cross-talk represents a new therapeutic opportunity in this challenging disease.
超过 30%的弥漫性大 B 细胞淋巴瘤(DLBCL)患者在一线治疗后治疗失败。中性粒细胞胞外诱捕网(NETs)是肿瘤微环境中的一种病原体捕获结构,可促进自身免疫向淋巴瘤发生的转变。在这里,我们研究了 NETs 是否在 DLBCL 进展中发挥新的作用及其潜在机制。通过免疫荧光和 ELISA 分别检测了 DLBCL 肿瘤样本和血浆中的 NETs。分析了 NETs 与临床特征之间的相关性。探讨了 NETs 对细胞增殖和迁移的影响及其机制,并通过一系列和试验研究了 NET 形成的机制。
血浆和肿瘤组织中 NETs 水平升高与 DLBCL 患者预后不良有关。此外,我们发现 NETs 增加了细胞增殖和迁移以及肿瘤生长和淋巴结转移。从机制上讲,DLBCL 衍生的 IL8 通过Src、p38 和 ERK 信号与中性粒细胞上的受体(CXCR2)相互作用,导致 NETs 的形成。新形成的 NETs 直接在上皮性 DLBCL 中上调 Toll 样受体 9(TLR9)途径,随后激活 NFκB、STAT3 和 p38 途径以促进肿瘤进展。更重要的是,破坏 NETs、阻断 IL8-CXCR2 轴或抑制 TLR9 可在临床前模型中减缓肿瘤进展。
我们的数据揭示了 DLBCL 中肿瘤-NETs 的侵袭性相互作用,并表明 NETs 是一种有用的预后生物标志物,靶向这种新的串扰代表了这种具有挑战性疾病的新治疗机会。